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Serum adenosine deaminase activity and the total
antioxidant capacity of plasma in pulmonary tuberculosis and
non-tuberculosis pulmonary disease
Mohammad NADERI1, Mohammad HASHEMI2, Ali MEHDIZADEH1, Hamid MEHRABIFAR1,
Hamid Reza KOUHPAYEH1, Hossein ANSARI3, Gholamreza BAHARI2, Saeid GHAVAMI4

Aim: The aim of this study was to investigate the level of serum adenosine deaminase (ADA) and the total antioxidant
capacity (TAC) in pulmonary tuberculosis (PTB), non-tuberculosis pulmonary disease (non-PTB) and healthy subjects.
Materials and methods: Serum ADA activity was measured using the Giusti and Galanti method, and the total
antioxidant capacity of plasma was determined by the ferric reducing ability of plasma (FRAP) test.
Results: The serum ADA levels were significantly higher (P < 0.001) in pulmonary TB (PTB, 19.78 ± 7.09 U/L), as well
as in non-PTB patients (14.78 ± 4.65 U/L) when compared to healthy controls (10.02 ± 1.99 U/L). The sensitivity and
specificity were found to be 71.7% and 63.3%, respectively, in distinguishing PTB from non-PTB. In distinguishing PTB
from healthy subjects, the sensitivity and specificity were 87% and 93.3%, respectively. The TAC was significantly lower
in PTB (485.2 ± 190.0 μM) and non-PTB patients (588.3 ± 195.8 μM), when compared to the controls (784.3 ± 190.0 μM;
P < 0.001). Plasma antioxidative activity decreased in PTB and non-PTB patients when compared to the controls.
Conclusion: We concluded that serum ADA activity is not a useful test to differentiate pulmonary TB from other
respiratory diseases. The TAC is low in pulmonary TB, therefore supplementation with a suitable anti-oxidant may be
useful.
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Introduction
Annually, more than 8 million people develop tuberculosis (TB), and approximately 1.8 million
cases result in death (1). TB has a long incubation period, with the timeline for transition from
infection to expression lastingmonths or decades. Therefore, it is not surprising that identification
of interspersion transmission events by classical epidemiological tools, like contact tracing, suffer
from recall and observer biases (2). The introduction of chemotherapeutic and prophylactic
measures had led to a substantial reduction in deaths, which was maintained for decades.
Regardless, TB is still responsible for the most human deaths caused by a single infectious agent (3).
Pulmonary TB continues to be a major health problem in the Sistan and Balouchistan provinces
of Iran, where it is the most prevalent disease.
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Adenosine deaminase (ADA) (E.C. 3.5.4.4.), an
enzyme responsible for the conversion of adenosine
and deoxyadenosine to inosine and deoxyinosine, is
involved in the proliferation and differentiation of
lymphocytes, particularly, the T subtype (4). It also
plays a role in the differentiation of lymphoid cells and
the maturation of monocytes to macrophages. The
presence of ADA in pericardial and other body fluids
reflects the activity of the cellular immune response
in the respective compartments, and in particular, the
activation of T lymphocytes and macrophages. ADA
has also been considered a marker of cell-mediated
immunity (5). Increased serum ADA activities were
observed in many infectious diseases caused by
microorganisms, which mainly infected macrophages.
Since Mycobacterium tuberculosis infects lung
macrophages, ADA may be released and detected in
the serum of patients with TB. Mycobacteria can
induce reactive oxygen species (ROS) production by
activating phagocytes (6), and though these are
important elements of the host’s defense against
mycobacteria, an enhanced ROS generation may
promote tissue injury and inflammation. This may
further contribute to immunosuppression,
particularly, in those with impaired antioxidant
capacity, such as HIV infected patients (7).
Furthermore, malnutrition, which is commonly
present in patients with TB, may contribute to their
impaired antioxidant capacity.
Direct (unconcentrated) sputum smears
microscopy is the primary test for diagnosing
pulmonary tuberculosis in developing countries. This
method is quick and inexpensive, but has relatively
low sensitivity. The in-vitro culture of mycobacterium
tuberculosis bacilli is the golden standard, but is timeconsuming (8). The polymerase chain reaction (PCR)
assay has shown good sensitivity and specificity in
several studies (9, 10), but it requires extreme
precision, accuracy, sophisticated lab equipment, and
skilled technicians. A rapid diagnostic test may be
helpful for a diagnosis of pulmonary disease (11).
Therefore, in this study we measured the level of
serum ADA to determine if it was a distinguishing
factor between pulmonary TB (PTB) and non-PTB
pulmonary disease (non-PTB) patients.
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Patients and methods
Patients
This case-control study was performed from
February 2006 to May 2007 at the Research Center for
Infectious Diseases and Tropical Medicine, Bou-Ali
Hospital, Zahedan University of Medical Sciences,
Zahedan, Iran. The project was approved by the
Ethical Committee of Zahedan University of Medical
Sciences, and an informed consent was given by all
patients and healthy individuals.
Blood samples were obtained from PTB (n = 85;
37 male, 48 female), non-PTB (n = 220; 120 male, 100
female), and healthy controls (n = 83; 50 male, 33
female). The diagnosis of PTB was based on clinical,
radiological, sputum Acid Fast Bacillus (AFB) smear
positivity, as well as culture and response to antituberculosis chemotherapy, as described previously
(11, 12). Non-PTB cases were identified as patients
showing signs and symptoms of acute pneumonia
(confirmed by chest X-ray), and for whom 3
consecutive sputum smears were negative for AFB.
The diagnosis of these patients was based on a
negative culture for mycobacterium tuberculosis
and/or clinical improvement and radiological
resolution on follow-up (11, 12). Normal subjects
were healthy individuals showing no signs, symptoms,
or history of pulmonary infections. The mean ages of
PTB patients, non-PTB patients, and healthy
individuals were 57.9 ± 18.5, 56.8 ± 17.1, and 38.4 ±
8.7 years, respectively. Age was significantly different
between PTB and healthy individuals (P < 0.0001),
while there was no significant difference between the
other patient groups (P = 0.83). The Body Mass Index
(BMI) was not significantly different between PTB
(20.2 ± 4.4 kg/m2) and non-PTB (20.9 ± 4.4 kg/m2) (P
= 0.339) patients, whereas it was significantly lower
in PTB and non-PTB when compared to normal
subjects (25.4 ± 3.8 kg/m2) (P < 0.05).
Measurement of Serum ADA activity and TAC
For the determination of ADA activity, serum
samples were obtained. For TAC measurement, blood
was drawn into anti-coagulated tubes containing
sodium EDTA, and plasma was separated by
centrifugation at 1500 × g for 10 min at +4 ºC, and
stored at -20 ºC until its use. ADA activity was
measured using the Giusti and Galanti method based
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on the Bertholet reaction (13). Briefly, the indophenol
complexes formed when ammonia was released from
adenosine and was quantified using a
spectrophotometer at a wavelength of 620 nm. One
unit of ADA was defined as the amount of enzyme
required to release one micromole of ammonia per
minute from adenosine at standard assay conditions.
ADA activity was expressed as units per liter (U/L) in
the serum.

The optimum cut-off value to differentiate ADA
activity between PTB and healthy controls was 12.5
U/L (Figure 2B). The sensitivity, specificity, positive
predictive value, and negative predictive values were
87%, 93.3%, 92.5%, and 84.1%, respectively (Table 1).

Plasma total antioxidant capacity (TAC) was
determined by the ferric reducing ability of plasma
(FRAP), which measures the ability of plasma to
reduce Fe3+ to Fe2+ (14).

There was no correlation between ADA activity
and TAC in pulmonary TB (r = -0.0256, P = 0.814),
and non-TB pulmonary disease (r = -0.0777, P =
0.251).

Plasma TAC of PTB (485.2 ± 190.0 μM) and nonPTB subjects (588.3 ± 195.8 μM) were significantly
lower than that of healthy subjects (784.3 ± 190.0 μM)
(Figure 3, P < 0.001).

Statistical analysis

Results
Serum ADA activity was significantly higher
(Figure 1, P < 0.001) in PTB (19.78 ± 7.09 U/L) as well
as non-PTB (14.78 ± 4.65 U/L) when compared to
healthy controls (10.02 ± 1.99 U/L). Additionally,
serum ADA activity was significantly higher in PTB
when compared to non-PTB controls (P < 0.05).
The optimum cut-off value for ADA was 16.5 U/L
in distinguishing PTB from non-PTB (Figure 2A).
The sensitivity, specificity, positive predictive, and
negative predictive value were found to be 71.7%,
63.3%, 42.8%, and 84.4%, respectively (Table 1).

Discussion
Adenosine deaminase (ADA) is essential for the
differentiation of lymphoid cells; in particular, T cells,
and is found to play an important role in the
maturation of monocytes to macrophages (15). Also,
ADA is considered to be an indicator of cell-mediated
immunity (16). Monocyte/macrophage activation by
intracellular infection and inflammatory diseases
leads to the release of ADA and elevated levels in
serum. Increased serum ADA levels in pulmonary TB
may result from a stimulation of cell-mediated
immunity (17).

Adenosine Deaminase Activity (U/L)

The results were expressed as mean ± S.D.
Commercial software (SPSS for Windows, v. 17) was
used for statistical analysis of variables. The normality
of the data was checked using Kolmogorov-Smirnov
test. Data was analyzed using one-way ANOVA, and
the Tukey multiple comparison test. The P-values <
0.05 were considered statistically significant. Pearson’s
correlation coefficient was used to determine the
relationship between variables. Receiver operating
characteristic (ROC) curves, and the area under the
ROC curves (AUC) with 95% confidence intervals,
were calculated for evaluating the optimum cut-off
level. The optimum cut-off level was determined by
selecting points of test values that provided the
greatest sum of sensitivity and specificity. Sensitivity,
specificity, positive predictive value, and negative
predictive value were determined.
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Figure 1. Serum ADA activity in pulmonary tuberculosis (PTB;
19.78 ± 7.09 U/L), non-tuberculosis respiratory disease
(non-PTB; 14.78 ± 4.65 U/L) and healthy controls
(10.02 ± 1.99 U/L). Serum ADA activity was
significantly higher in pulmonary tuberculosis, as well
as non-tuberculosis respiratory disease, when
compared to healthy controls (P < 0.001).
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Figure 2. The ROC curve analysis for determining the optimum cut-off point in distinguishing PTB from non-PTB patients (2A) and
the controls (non-PTB patients and healthy subjects) (2B). The optimum cut-off points were found to be 12.5 U/L and 16.5
U/L, respectively, in distinguishing TB from non-PTB, and TB from control subjects, respectively.
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We report that the serum concentration of ADA|
was significantly higher (P < 0.001) in pulmonary TB
(19.78 ± 7.09 U/L), as well as non-TB pulmonary
disease (14.78 ± 4.65 U/L) when compared to the
control group (10.02 ± 1.99 U/L). A number of groups
have reported different values for normal human
serum ADA activity: 5.9 ± 17.6 U/L (18), 13.04 ± 3.3
(19), 8.58 ± 4.38 U/L (20), 14.0 ± 0.5 U/L, 10.31 ± 0.58
U/L (21), 16.5 ± 3.18 U/L(22), 11.1 ± 3.0 U/L (23),
and 2.23 ± 1.0 U/L (24). Our findings were similar to
those of previous studies (25-27).
For several years, the ability to differentiate the
diagnosis of PTB and non-PTB was an important
issue for clinicians. As such, many techniques have
been used to address this aim. Serum ADA activity is
one such method, for which there have been varying
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Table 1. The optimum cut-off level of ADA was found to be 16.5
U/L in distinguishing pulmonary tuberculosis (PTB)
from non-TB pulmonary disease (non-PTB). Sensitivity,
specificity, positive predictive value and negative
predictive value were found to be71.7%, 63.3%, 42.8%
and 84.4%, respectively.
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Figure 3. Comparison of the TAC of plasma in pulmonary
tuberculosis (PTB), non-tuberculosis respiratory
disease (non-PTB) and healthy subjects. The TAC was
significantly lower in pulmonary tuberculosis, as well
as non-tuberculosis respiratory disease when compared
to healthy controls (P < 0.001).

results. Lamsal et al. found a cut-off value of 25 U/L,
a test sensitivity of 72.41%, and a specificity of 81.53%
(25). Kuyucu et al. reported a serum ADA level of
greater/equal to 53.76 U/L, a sensitivity of 100%, and
a specificity of 90.7%, while indicating a positive
predictive value of 58.8%, and a negative predictive
value of 100% in children with TB (17). Bhargave et al.
and Al-Shammary et al. reported the cut-off value of
serum ADA levels in tuberculosis patients as 78.12
IU/L and 32.8 U/L, respectively (5, 27). ADA activity
has been shown to be higher in children with active
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TB, than in children with bacterial or viral pneumonia
(28). In our study, the optimum cut-off point of ADA
for distinguishing PTB and non-PTB subjects was
found to be 16.5 U/L using the ROC curve. Therefore,
according to our divisive results, it can be concluded
that serum ADA activity might not be a suitable test
for distinguishing pulmonary TB and non-TB
pulmonary disease.
Free radical formation is a consequence of a
variety of essential biochemical reactions and could
be unregulated under pathophysiological conditions
(29). Antioxidants play an important physiological
role counteracting free radicals and preventing
cellular damage. Lung inflammation occurs during
TB infection and is a source of free radical generation.
It was reported that patients with advanced TB had
increased levels of lipid peroxidation products and
malondialdehyde (30). Our study also showed that
plasma TAC was significantly decreased in patients
with PTB or non-PTB when compared to the controls.
This finding was previously reported by Wiid et al.,
who found that the antioxidant status was decreased
in active TB patients when compared to controls, but
was subsequently increased during the therapeutic
procedure. This suggests that the disease contributed
to the depleted antioxidant status of the patients, not

only via the inflammatory side effects of the disease,
but perhaps, also through the lowered nutritional
intake as a consequence of the disease. In TB,
oxidative stress is a result of tissue inflammation and
free radical rupture from activated macrophages (31).
These free radicals may cause pulmonary
inflammation if they are not scavenged by
antioxidants. Therefore, TAC is a suitable indicator of
the free radical load, and antioxidant supplement
might be a good therapeutic protocol in TB and nonPTB patients with a low TAC.
In conclusion, although serum the ADA
measurement is simple and inexpensive, it is not a
useful test to differentiate PTB from other respiratory
diseases, due to its low sensitivity and specificity.
However, TAC may be a valid approach to determine
the antioxidant status of TB and non-PTB patients.
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